At the Annual General Meeting on 26 March 2026, the Board of Directors will propose a final dividend of DKK 7.95 per share for 2025, taking the expected total dividend for 2025 to 11.70. The Board of Directors has decided to initiate a new share repurchase programme of up to DKK 15 billion. Adjusted sales growth for 2026, which excludes revenue from the reversal of 340B provisions, is expected to ...
At the Annual General Meeting on 26 March 2026, the Board of Directors will propose a final dividend of DKK 7.95 per share for 2025, taking the expected total dividend for 2025 to 11.70. The Board of Directors has decided to initiate a new share repurchase programme of up to DKK 15 billion. Adjusted sales growth for 2026, which excludes revenue from the reversal of 340B provisions, is expected to be -5 to -13% at CER. Adjusted sales growth reported in Danish kroner is expected to be 3 percentage points lower than at CER. The sales outlook is impacted by lower realised prices, including impacts related to the "Most Favoured Nations" agreement in the US and the patent expiry of the semaglutide molecule in certain IO markets, as well as competition. The global GLP-1 market is expected to continue to expand with Novo Nordisk introducing new treatments, such as Wegovy ® pill and higher doses of Wegovy ® , enabling Novo Nordisk to continue to increase patient reach and expand volumes. Adjusted operating profit growth is expected to be -5 to -13% at CER. Adjusted operating profit growth reported in Danish kroner is expected to be 5 percentage points lower than at CER. Sales and operating profit for 2026 will be positively impacted by a reversal of sales rebate provisions of USD 4.2 billion related to the 340B Drug Pricing Program in the US. Key R&D developments in the quarter include the phase 2 trial with zenagamtide (previously amycretin) showing significant weight loss and HbA 1c reduction in type 2 diabetes, and the phase 3 trial REIMAGINE 2 with CagriSema, also in diabetes, was successfully completed. Within obesity, Novo Nordisk has submitted semaglutide 7.2 mg and the next-generation asset CagriSema to the US FDA. On 22 December, the US FDA approved the first oral GLP-1 in obesity, once-daily oral semaglutide 25 mg, under the brand name of Wegovy ® pill. Wegovy ® pill was launched on 5 January 2026, and as of 23 January, total weekly prescriptions amounted to around...
hapabapa AbbVie ( ABBV ) is expected to report a 23% surge in its fourth-quarter earnings, scheduled for February 4, before the opening bell. The company’s EPS is seen coming in at $2.65, while revenue is projected to jump 8.7% to $16.41B. In January, the company had said that it expects to incur acquired IPR&D and milestone expenses of $1.3B in its Q4 financial results, leading to a -$0.71 impact...
hapabapa AbbVie ( ABBV ) is expected to report a 23% surge in its fourth-quarter earnings, scheduled for February 4, before the opening bell. The company’s EPS is seen coming in at $2.65, while revenue is projected to jump 8.7% to $16.41B. In January, the company had said that it expects to incur acquired IPR&D and milestone expenses of $1.3B in its Q4 financial results, leading to a -$0.71 impact to GAAP and non-GAAP diluted EPS. The company said its Q4 diluted EPS guidance range, including the impact of the IPR&D and milestones expense, is $2.61-$2.65. Over the last 3 months, EPS estimates have seen no upward revisions but have witnessed 12 downward moves. Revenue estimates have seen 12 upward revisions and 2 downward moves. Analysts at Bernstein noted that the company has had a strong run-up this year, driven by growing recognition of Skyrizi and Rinvoq’s earnings potential, demonstrated by consistent quarterly beats. The company is expected to maintain the momentum. Going forward, IBD trial results will be critical for AbbVie because of intensifying competition in this treatment area. For instance, ABBV faces rising competition from JNJ’s ( JNJ ) Tremfya in IBD. 2026 is also expected to be a catalyst-rich year across AbbVie’s three core pillars- immunology, oncology, and neuroscience, Bernstein said. “We should expect to see more deals from AbbVie in 2026 as the company looks to augment growth in the early 2030s. In particular, they have signaled that they would like to complement the obesity asset they acquired from Gubra, an amylin, with a partner molecule,” it additionally noted. AbbVie is projected to guide 2026 in line with estimates but is likely to raise long-term guidance on Skyrizi/Rinvoq. Over the last 2 years, ABBV has beaten EPS estimates 63% of the time and has beaten revenue estimates 100% of the time. More on AbbVie AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript AbbVie: The Dividend Does Not Lie AbbVie: Roc...
Grandbrothers/iStock Editorial via Getty Images Prelude Therapeutics ( PRLD ) traded higher on Tuesday after the Wilmington, Delaware-based biotech received FDA clearance to advance an early-stage trial for its blood cancer candidate PRT12396 developed with Incyte ( INCY ). The company said that the agency greenlighted its Investigational New Drug Application for PRT12396, which is designed to tar...
Grandbrothers/iStock Editorial via Getty Images Prelude Therapeutics ( PRLD ) traded higher on Tuesday after the Wilmington, Delaware-based biotech received FDA clearance to advance an early-stage trial for its blood cancer candidate PRT12396 developed with Incyte ( INCY ). The company said that the agency greenlighted its Investigational New Drug Application for PRT12396, which is designed to target a group of blood cancers known as myeloproliferative neoplasms. The Phase 1 trial is expected to evaluate PRT12396 in high-risk polycythemia vera and intermediate and high-risk myelofibrosis, with its dosing expected to begin in Q2 2026. The open-label, multi-center study is designed to evaluate the safety and efficacy of the drug as some of its primary endpoints. PRT12396 is part of Prelude’s ( PRLD ) JAK2V617F JH2 inhibitor program, which represents candidates targeting a genetic mutation called JAK2V617F, the key factor leading to the progression of a majority of myeloproliferative neoplasms. More on Prelude Therapeutics, Incyte What Investors Should Know Before Buying Incyte Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Incyte: Buy For The Turnaround, Stay For The Pipeline Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy
Novo Nordisk A/S Bagsværd, Denmark, 3 February 2026 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER. 2025 sales and operating profit growth at CER In 2025, Novo Nordisk’s sales increased by 10% and operating profit increased by 6%, compared to previously issued guida...
Novo Nordisk A/S Bagsværd, Denmark, 3 February 2026 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER. 2025 sales and operating profit growth at CER In 2025, Novo Nordisk’s sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and 4 to 7% operating profit growth1. Sales in US Operations were positively impacted by gross-to-net sales adjustments. Profit and loss (CER) Q4 2025 FY 2025 Sales growth -2% 10% Operating profit growth (EBIT) -4% 6% 2026 sales and operating profit outlook at CER Sales and operating profit for 2026 will be positively impacted by a reversal of sales rebate provisions of USD 4.2 billion related to the 340B Drug Pricing Program in the US. Novo Nordisk will, from 2026, present outlook for sales and operating profit using new non-IFRS measures of adjusted sales growth and adjusted operating profit growth. This is introduced to exclude certain exceptional and non-recurring effects, primarily of non-cash nature, including the impact in the first quarter of 2026 from reversal of sales rebate provisions of USD 4.2 billion related to the 340B Drug Pricing Program. In the event of other exceptional, non-recurring items related to effects from major legal matters and major impairment losses, these will also be excluded from adjusted operating profit to enhance transparency and comparability of underlying operating performance. Both adjusted sales and operating profit growth exclude positive impacts from the reversal of provision related to the 340B Drug Pricing Program. In 2025, USD 400 million has been excluded, and in 2026, USD 4.2 billion has been excluded. On a non-adjusted basis, the mid-point of sales and operating profit growth guidance for 2026, both at CER, would be -1% and 11%, respectively. Outlook 2026 (CER) Full year expectations 3 February Ad...
The Fed cited signs of stabilization in employment when it held interest rates steady on Wednesday, after easing monetary policy in late 2025 in response to a weakening labor market. Investors will look for evidence of a strengthening U.S. jobs market in the monthly employment report on February 6th, as they assess the prospects for further rate cuts. World Gold Council data showed gold demand hi...
The Fed cited signs of stabilization in employment when it held interest rates steady on Wednesday, after easing monetary policy in late 2025 in response to a weakening labor market. Investors will look for evidence of a strengthening U.S. jobs market in the monthly employment report on February 6th, as they assess the prospects for further rate cuts. World Gold Council data showed gold demand hit an all-time high last year, as jitters over instability and trade sparked a surge in investment. But sky-high prices have already hit jewelry demand and are set to dampen central bank buying, according to the organization. And there seems no shortage of triggers to provide more support for everyone's favourite safe haven: a fracturing world order, a potential attack on Iran, a falling dollar, worries about Fed independence and renewed trade turmoil. Expectations that Warsh could be more hawkish saw gold scuttle away from its near-$5,600 record high, but it's still on track for a 20% rally in January — its strongest month since 1980. The breathtaking rally that has lifted gold (and silver, platinum and palladium for that matter) to record highs might be showing a few cracks. Plus, former Federal Reserve Governor Kevin Warsh has been confirmed as the next head of the central bank. · U.S. jobs data could bring new headwinds or tailwinds for the dollar, and Financial markets are heading towards the end of an unforgettable January, not least thanks to the U.S. dollar — set for its worst start to the year since 2018, and the coming week brings a set of catalysts that could shake things up further. What is going on in this Global Week Ahead? Chicago, IL – February 3, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet GOOGL, Amazon AMZN, ASML Holdings ASML, Micron MU and Lam ...
The Fed cited signs of stabilization in employment when it held interest rates steady on Wednesday, after easing monetary policy in late 2025 in response to a weakening labor market. Investors will look for evidence of a strengthening U.S. jobs market in the monthly employment report on February 6th, as they assess the prospects for further rate cuts. World Gold Council data showed gold demand hi...
The Fed cited signs of stabilization in employment when it held interest rates steady on Wednesday, after easing monetary policy in late 2025 in response to a weakening labor market. Investors will look for evidence of a strengthening U.S. jobs market in the monthly employment report on February 6th, as they assess the prospects for further rate cuts. World Gold Council data showed gold demand hit an all-time high last year, as jitters over instability and trade sparked a surge in investment. But sky-high prices have already hit jewelry demand and are set to dampen central bank buying, according to the organization. And there seems no shortage of triggers to provide more support for everyone's favourite safe haven: a fracturing world order, a potential attack on Iran, a falling dollar, worries about Fed independence and renewed trade turmoil. Expectations that Warsh could be more hawkish saw gold scuttle away from its near-$5,600 record high, but it's still on track for a 20% rally in January — its strongest month since 1980. The breathtaking rally that has lifted gold (and silver, platinum and palladium for that matter) to record highs might be showing a few cracks. Plus, former Federal Reserve Governor Kevin Warsh has been confirmed as the next head of the central bank. · U.S. jobs data could bring new headwinds or tailwinds for the dollar, and Financial markets are heading towards the end of an unforgettable January, not least thanks to the U.S. dollar — set for its worst start to the year since 2018, and the coming week brings a set of catalysts that could shake things up further. What is going on in this Global Week Ahead? Chicago, IL – February 3, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet GOOGL, Amazon AMZN, ASML Holdings ASML, Micron MU and Lam ...
asbe/iStock via Getty Images Shares of PayPal ( PYPL ) tumbled 19.3% on Tuesday after the fintech company delivered a disappointing quarterly update, posting weaker-than-expected Q4 earnings and revenue alongside downbeat forward guidance. The sharp decline quickly rippled through the ETF landscape, pressuring funds with notable exposure to PYPL. PayPal is a widely held name across ETFs, currently...
asbe/iStock via Getty Images Shares of PayPal ( PYPL ) tumbled 19.3% on Tuesday after the fintech company delivered a disappointing quarterly update, posting weaker-than-expected Q4 earnings and revenue alongside downbeat forward guidance. The sharp decline quickly rippled through the ETF landscape, pressuring funds with notable exposure to PYPL. PayPal is a widely held name across ETFs, currently appearing in 350 funds with a combined total of roughly 169M shares held. As a result, large single-day moves in PYPL can translate into meaningful performance headwinds for ETFs with heavier allocations. Below are 10 ETFs with the largest portfolio allocations to PayPal, highlighting where the stock’s latest slide may be felt most acutely: No. 1: Direxion Daily Crypto Industry Bull 2X Shares ( LMBO ), 6.25% allocation No. 2: Amplify Digital Payments ETF ( IPAY ), 5.29% allocation No. 3: Global X FinTech ETF ( FINX ), 4.72% allocation No. 4: Trenchless Fund ETF ( RVER ), 3.91% allocation No. 5: Amplify Stablecoin Technology ETF ( STBQ ), 3.77% allocation No. 6: First Trust Bloomberg Shareholder Yield ETF ( SHRY ), 3.76% allocation No. 7: YieldMax Crypto Industry & Tech Portfolio Option Income ETF ( LFGY ), 3.60% allocation No. 8: Motley Fool Value Factor ETF ( MFVL ), 3.53% allocation No. 9: REX Crypto Equity Premium Income ETF ( CEPI ), 3.36% allocation No. 10: Matrix Advisors Value ETF ( MAVF ), 2.87% allocation FinTech ETFs: ( ARKF ), ( FINX ), ( DARP ), and ( BPAY ). More on markets SpaceX–xAI deal reignites IPO countdown as prediction markets take bets on the date PLTR jumps on earnings; see what SA analysts are saying Deutsche Bank stands firm on $6,000 gold target as it says the bullish case remains intact ETF inflows shatter records as $165B floods in during the month of January U.S. corporate profits stay on solid footing, as Goldman projects double-digit growth in 2026
In this article MP USAR Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 6:16 06:16 Jovanovic: Project Vault puts America’s best foot forward Worldwide Exchange The Trump administration's new minerals stockpile initiative – dubbed "Project Vault" – can include anything identified as "critical" by the U.S. Geological Survey, a White House official told CNBC Tuesday. The agency, part ...
In this article MP USAR Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 6:16 06:16 Jovanovic: Project Vault puts America’s best foot forward Worldwide Exchange The Trump administration's new minerals stockpile initiative – dubbed "Project Vault" – can include anything identified as "critical" by the U.S. Geological Survey, a White House official told CNBC Tuesday. The agency, part of the Interior Department, lists more than 50 minerals as critical. They include rare earths, lithium, uranium and copper as "essential for national security, economic stability and supply chain resilience." The minerals are crucial because they "underpin key industries, drive technological innovation, and support critical infrastructure vital for a modern American economy," according to USGS . President Donald Trump on Monday unveiled "Project Vault," which is a first-of-its-kind public-private partnership. The U.S. Export-Import Bank will provide $10 billion in the form of a loan, with about $2 billion coming from private capital. "You're covering everything with this," Trump said during an event at the White House on Monday. "We're not just doing certain minerals and rare earths. We're doing everything." Equipment manufacturers including GE Vernova, Western Digital and Boeing have expressed interest, said EXIM Bank Chairman John Jovanovic in a statement Monday. General Motors CEO Mary Barra attended the White House event that unveiled the stockpile. "Having a resilient supply chain is critical for our nation, and it's critical for all industry, especially the auto industry," Barra said at the White House. Beyond autos, critical minerals are key inputs for the defense, robotics, semiconductor, electronics and energy industries. The stockpile is the latest move by the Trump administration to build a Western supply chain to counter China's dominance in critical minerals – especially when it comes to refining. Beijing sought to cut off exports of rare earths , a subset of c...
Donald Trump’s administration has turned to an unusual weapon in its attempt to resurrect coal mining – a cartoon lump of coal, complete with giant eyes and yellow mining garb, called ‘Coalie.’ The administration’s new mascot, kitted out with a helmet, boots and gloves, was introduced in a seemingly artificial intelligence-generated picture posted online by Doug Burgum, Trump’s interior secretary....
Donald Trump’s administration has turned to an unusual weapon in its attempt to resurrect coal mining – a cartoon lump of coal, complete with giant eyes and yellow mining garb, called ‘Coalie.’ The administration’s new mascot, kitted out with a helmet, boots and gloves, was introduced in a seemingly artificial intelligence-generated picture posted online by Doug Burgum, Trump’s interior secretary. “Mine, Baby, Mine!” Burgum wrote on X, adding that Coalie will act as a “spokesperson” for Trump’s “American Energy Dominance Agenda.” Climate activists criticized the latest attempt by the administration to boost the image of the dirtiest fossil fuel despite its impacts on the planet and public health, with one critic describing it as “one of the most heinous ways to produce energy that our world has ever seen.” Coalie, whose large eyes and grin appears to invoke a Japanese style of cuteness used in toys and animated characters, is to be an ambassador for the Office of Surface Mining Reclamation and Enforcement (OSMRE), the US government agency responsible for regulating coalmines. View image in fullscreen Donald Trump and Doug Burgum speak in West Palm Beach, Florida, on 19 January 2026. Photograph: Julia Demaree Nikhinson/AP Further images of Coalie appear on the OSMRE website, where the anthropomorphic hunk of carbon is depicted joyfully posing with what appeared to be an AI-generated family, standing on an office table during a meeting while giving cheeky wink and happily showing off an abandoned coalmine that has been turned into a bucolic picnic site. The image of Coalie was first created in 2018 when a social media manager at OSMRE put googly eyes on a picture of coal, according to Grist. The new public use of Coalie to promote Trump’s agenda is the latest attempt by the administration to revamp a US coal industry that has declined sharply in the past decade despite the president’s promises to reverse the fortunes of the industry’s dwindling workforce. “I have a li...
A secondary school pupil stabbed an art teacher in southern France on Tuesday, leaving the 60-year-old in critical condition, a prosecutor said. The pupil, in a class of early teenagers, stabbed the teacher at least three times. He was later arrested on suspicion of attempted murder, said Raphael Balland, the public prosecutor in the southern city of Toulon. There were no known “religious or polit...
A secondary school pupil stabbed an art teacher in southern France on Tuesday, leaving the 60-year-old in critical condition, a prosecutor said. The pupil, in a class of early teenagers, stabbed the teacher at least three times. He was later arrested on suspicion of attempted murder, said Raphael Balland, the public prosecutor in the southern city of Toulon. There were no known “religious or political connotations” at this stage, said Balland. Advertisement “All we know is that there had been tensions with this teacher recently, and that he was angry with her,” the prosecutor added during a press briefing. France’s education minister, Edouard Geffray, said he was headed to La Guicharde secondary school, where the stabbing took place, in the town of Sanary-sur-Mer. Students and their parents stand in front of the La Guicharde middle school after a teacher was stabbed on Tuesday. Photo: Reuters “My thoughts immediately go out to the victim, her family and the entire educational community, whose deep shock I share,” he wrote on social media.
Apple Inc. (NASDAQ:AAPL) is one of the stocks Jim Cramer shed light on recently. Cramer showed optimism around the company’s latest quarter and the stock, as he commented: People are way too eager to give up on Apple… I think Apple’s quarter was fantastic and its future remains bright… Apple took the whole supply chain by surprise. I am an Apple aficionado from way back proudly, and I know how lit...
Apple Inc. (NASDAQ:AAPL) is one of the stocks Jim Cramer shed light on recently. Cramer showed optimism around the company’s latest quarter and the stock, as he commented: People are way too eager to give up on Apple… I think Apple’s quarter was fantastic and its future remains bright… Apple took the whole supply chain by surprise. I am an Apple aficionado from way back proudly, and I know how little hype there is from this company… I don’t believe that Cook and his team would be so ebullient about their discussion of Apple’s current position with me if they knew the component prices were going sky high and they’d have shortfalls galore, which is how the stock was trading earlier today. What would allow Apple to overcome these shortages? First, we don’t know how much supply they have stockpiled… brandon-romanchuk-NOFyRmSQfUQ-unsplash Apple Inc. (NASDAQ:AAPL) manufactures and sells devices such as the iPhone, Mac, iPad, along with its line-up of wearables and accessories. The devices are supported by the company’s app ecosystem, AppleCare, and cloud tools.